Asthma – Pipeline Review, H1 2013

Global Markets Direct’s, ‘Asthma – Pipeline Review, H1 2013′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Asthma. Asthma – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Asthma.
- A review of the Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Asthma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products..

Get Report Details @ http://www.rnrmarketresearch.com/asthma-pipeline-review-h1-2013-market-report.html

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Asthma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Asthma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Inquiry For Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=86244

Table of Content

Table of Contents 2
List of Tables 6
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Asthma Overview 13
Therapeutics Development 14
An Overview of Pipeline Products for Asthma 14
Asthma Therapeutics under Development by Companies 16
Asthma Therapeutics under Investigation by Universities/Institutes 28
Late Stage Products 30
Comparative Analysis 30
Mid Clinical Stage Products 31
Comparative Analysis 31
Early Clinical Stage Products 32
Comparative Analysis 32
Discovery and Pre-Clinical Stage Products 33
Comparative Analysis 33
Asthma Therapeutics - Products under Development by Companies 34
Asthma Therapeutics - Products under Investigation by Universities/Institutes 52
Companies Involved in Asthma Therapeutics Development 54
Alcon, Inc. 54
Johnson & Johnson 55
Boehringer Ingelheim GmbH 56
F. Hoffmann-La Roche Ltd. 57
Kyowa Hakko Kirin Co., Ltd. 58
EpiGenesis Pharmaceuticals, Inc. 59
Amgen Inc. 60
AstraZeneca PLC 61
GlaxoSmithKline plc 62
Genentech, Inc. 63
Biotec Pharmacon ASA 64
MedImmune LLC 65
Daiichi Sankyo Company, Ltd 66
Merck & Co., Inc. 67
Nissan Chemical Industries, Ltd. 68
Dainippon Sumitomo Pharma Co., Ltd. 69
Novo Nordisk A/S 70
Infinity Pharmaceuticals, Inc. 71
SkyePharma PLC 72
Albany Molecular Research, Inc. 73
Vectura Group plc 74
BioLineRx, Ltd. 75
Novartis AG 76
Isotechnika Pharma Inc. 77
Actelion Ltd 78
ALK-Abello A/S 79
ASKA Pharmaceutical Co., Ltd 80
Astellas Pharma Inc. 81
Chiesi Farmaceutici SpA 82
Dong-A Pharmaceutical Co., Ltd. 83
Forest Laboratories, Inc. 84
Glenmark Pharmaceuticals Ltd. 85
Kissei Pharmaceutical Co., Ltd. 86
Ono Pharmaceutical Co., Ltd. 87
Orion Corporation 88
Pfizer Inc. 89
Rigel Pharmaceuticals, Inc. 90
Teva Pharmaceutical Industries Limited 91
Zambon Group S.p.A. 92
Sun Pharmaceutical Industries Limited 93
OPKO Health, Inc. 94
iCo Therapeutics Inc. 95
Antisense Therapeutics Limited 96
Idera Pharmaceuticals, Inc. 97
Lotus Pharmaceuticals, Inc. 98
Almirall, S.A. 99
Compugen Ltd. 100
Pacgen Biopharmaceuticals Corporation 101
Palatin Technologies, Inc. 102
Pharmaxis Ltd. 103
Alexion Pharmaceuticals, Inc. 104
Portola Pharmaceuticals, Inc. 105
Cytokinetics, Inc 106
Yuhan Corporation 107
WhanIn Pharmaceutical Co., Ltd. 108
Regeneron Pharmaceuticals, Inc. 109
NeoStem, Inc. 110
Array BioPharma Inc. 111
Dynavax Technologies Corporation 112
Phytopharm Plc 113
Stallergenes S.A. 114
Torii Pharmaceutical Co., Ltd. 115
Cytos Biotechnology AG 116
Ahn-Gook Pharmaceutical Co., Ltd. 117
HYUNDAI PHARM. CO., LTD. 118
Neurim Pharmaceuticals (1991) Ltd. 119
Synairgen plc 120
Panacea Biotec Limited 121
Orexo AB 122
Clavis Pharma ASA 123
Amphastar Pharmaceuticals, Inc. 124
Verona Pharma Plc 125
Morphotek, Inc. 126
Marinomed Biotechnologie GmbH 127
Alba Therapeutics Corporation 128
Allergopharma Joachim Ganzer KG 129
Immupharma Plc 130
Palau Pharma S.A 131
Farmacija d.o.o. Tuzla 132
Pieris AG 133
Respiratorius AB 134
Aquinox Pharmaceuticals Inc. 135
Nostrum Pharmaceuticals, LLC 136
Promedior, Inc. 137
Oxagen Limited 138
Heat Biologics, Inc. 139
Pulmatrix, Inc. 140
Axikin Pharmaceuticals, Inc. 141
Opsona Therapeutics Ltd. 142
Five Prime Therapeutics, Inc. 143
MSM Protein Technologies, Inc. 144
Indus Biotech Private Limited 145
AIM Therapeutics Inc. 146
Hydra Biosciences, Inc. 147
Txcell SA 148
Theraclone Sciences, Inc. 149
Vantia Therapeutics 150
Biotica Technology Ltd 151
Monosol Rx, LLC 152
NKT Therapeutics, Inc. 153
Transtech Pharma, Inc. 154
Xencor, Inc. 155
Cornerstone Therapeutics Inc. 156
Targacept, Inc. 157
BaroFold, Inc. 158
Sparsha Pharma International Pvt. Ltd. 159
Cellceutix Corporation 160
CBio Limited 161
KaloBios Pharmaceuticals, Inc. 162
AB Science 163
Resolvyx Pharmaceuticals, Inc 164
Adamis Pharmaceuticals Corporation 165
Savara, Inc. 166
Asmacure Limited 167
RespiVert Ltd. 168
ISU ABXIS Co.,Ltd. 169
MicroDose Therapeutx, Inc. 170
N30 Pharmaceuticals 171
Immune Technologies and Medicine 172
Clarassance, Inc. 173
Asthma - Therapeutics Assessment 174
Assessment by Monotherapy Products 174
Assessment by Combination Products 175
Assessment by Route of Administration 176
Assessment by Molecule Type 179
Drug Profiles 182
lebrikizumab - Drug Profile 182
mepolizumab - Drug Profile 184
Veramyst - Drug Profile 186
omalizumab - Drug Profile 189
reslizumab - Drug Profile 191
(fluticasone proprionate + formoterol fumarate) - Drug Profile 192
(fluticasone proprionate + formoterol fumarate) - Drug Profile 194
(fluticasone furoate + vilanterol trifenatate) - Drug Profile 196
(fluticasone furoate + vilanterol trifenatate) - Drug Profile 198
Mitizax - Drug Profile 200
masitinib - Drug Profile 201
Staloral - Drug Profile 203
azithromycin - Drug Profile 204
epinephrine - Drug Profile 205
MK-7243 - Drug Profile 207
terbutaline sulphate - Drug Profile 209
Acaroid - Drug Profile 210
tiotropium bromide - Drug Profile 211
andolast - Drug Profile 213
Depigoid + [omalizumab] - Drug Profile 214
Fluticasone Propionate + Salmeterol - Drug Profile 215
tulobuterol - Drug Profile 216
IP-033 - Drug Profile 217
(fluticasone + formoterol) - Drug Profile 218
OM-85 - Drug Profile 219
TO-204 - Drug Profile 220
budesonide - Drug Profile 221
Asthma Therapeutics - Drug Profile Updates 222
Asthma Therapeutics - Discontinued Products 245
Asthma Therapeutics - Dormant Products 250
Asthma - Product Development Milestones 269
Featured News & Press Releases 269
Appendix 276
Methodology 276
Coverage 276
Secondary Research 276
Primary Research 276
Expert Panel Validation 276
Contact Us 277
Disclaimer 277